Empfehlungen und Perspektiven der antiretroviralen Therapie

Die Entwicklung der medikamentösen Therapie der Infektion mit dem humanen Immunschwäche-Virus (HIV) hat zu einem vollständigen Wandel dieses Krankheitsbildes vor allem hinsichtlich der Lebenserwartung und der Infektion mit opportunistischen Erregern geführt. Im vorliegenden Artikel soll ein Einblick in den aktuellen Stand der Therapie aber auch ein Ausblick auf zukünftigen Therapieoptionen gegeben werden.

Literatur

• 1 Frankel A D, Young J AT. HIV-1: Fifteen proteins and an RNA.  Annu Rev Biochem. 1998;  67 1-25
• 2 Furman P A, Barry D W. Spectrum of antiviral activity and mechanism of action of zidovudine.  Am J Med. 1988;  85 177-181
• 3 Prelson A S, Essunger P, Cao Y. et al . Decay characteristics of HIV-1 infected compartments during combination therapy.  Nature. 1997;  387 188-191
• 4 Hockett R D, Kilby J M, Derdeyn C A. et al . Constant mean viral copy number per infected cell in tissues regardless of high, low or undetectable plasma HIV-RNA.  J Exp Med. 1999;  189 1545-1559
• 5 Finzi D, Blankson J, Siliciano J D. et al . Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.  Nat Med. 1999;  5 512-517
• 6 Centers for Disease Control and Prevention . 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.  MMWR. 1992;  41 1-19
• 7 Gulick R M, Mellors J W, Havlie D. et al . Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.  N Engl J Med. 1997;  337 734-739
• 8 Cameron D W, Heath-Chiozzi M, Danner. et al. and the Advanced HIV Disease Ritonavir Study Group . Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease.  Lancet. 1998;  351 543-549
• 9 Panel on Clinical Practices for Treatment of HIV Infection . Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.  JAMA. 2001;  2 1-108
• 10 Powderly W G, Saag M S, Chapman S. et al . Predictors of optimal virological response to potent antiretroviral therapy.  AIDS. 1999;  13 1873-1880
• 11 Deeks S G, Hecht F M, Swanson M. et al . HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy.  AIDS. 1999;  13 F35-43
• 12 Daar E S, Little S, Pitt J. et al . Diagnosis of primary HIV-1 infection.  Ann Intern Med. 2001;  134 25-29
• 13 Lillo F B, Ciuffreda D, Veglia F. et al . Viral load and burden modification following early antiretroviral therapy of primary HIV infection.  AIDS. 1999;  13 791-796
• 14 Altfeld M, Rosenberg E S. The role of CD4+ T helper cells in the cytotoxic T lymphocyte response to HIV-1.  Curr Op Immunol. 2000;  12 375-380
• 15 Consensus Statement . Antiretroviral therapy in adults. Updated recommendations of the International Society-USA Panel.  JAMA. 2000;  283 381-390
• 16 Staszewski S, Keiser P, Gathe J. et al .Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naïve adults at 48 weeks. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1999: Abstract 505
• 17 Katlama C, Clumeck N, Fenske S. et al .Use of Trizivir to simplify therapy in HAART-experienced patients with long-term suppression of HIV-RNA: TRIZAL-Study - 24 week results. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001: Abstract 316
• 18 King M, Bernstein B, Kempf D. et al .Comparison of time to achieve HIV RNA <400 copies/ml and <50 copies/ml in a Phase III, blinded, randomized clinical trial of ABT-378/r vs. NFV in ARV-naïve patients. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001: Abstract 329
• 19 Ledergerber B, Egger M, Opravil M. et al . Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study.  Lancet. 1999;  353 863-868
• 20 Deeks S G, Wrin T, Liegler T. et al . Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.  N Engl J Med. 2001;  244 472-480
• 21 Montaner J SG, Harrigan P R, Jahnke N. et al . Multple drug rescue therapy (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens.  AIDS. 2000;  15 63-71
• 22 Deeks S G, Martin J N. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient.  AIDS. 2001;  15 117-119
• 23 Friedrich M J. HAART stopping news: experts examine structured therapy interruption for HIV.  JAMA. 2000;  283 2917-2918
• 24 Phillips A, Youle M, Tyrer M. et al .CD4 count change in people interrupting HAART therapy after CD4 count increase. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001: Abstract 361
• 25 Rosenberg E S, Altfeld M, Poon S H. et al . Immune control of HIV-1 after early treatment of acute infection.  Nature. 2000;  407 523-526
• 26 Miro J M, Tortajada C, Plana M. et al .HIV-1 specific T-cell responses and spontaneous control of viremia can be detected after the first cycle of structured therapy interruptions in patients receiving HAART since primary HIV-1 infection. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001: Abstract 359
• 27 Armstrong W S, Kazanjian P. Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin and interleukin-2.  Clin Infect Dis. 2001;  32 766-773
• 28 De Clercq E. The emerging role of fusion inhibitors on HIV infection.  Drugs R D. 1999;  2 321-331
• 29 Kilby J M, Hopkins S, Venetta T M. et al . Potent suppression of HIV-1 replication in humans by T-20, a inhibitor of gp41-mediated virus entry.  Nat Med. 1998;  4 1302-1307
• 30 Tremblay C L, Kollmann C, Giguel F. et al . Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.  J Acquir Immune Defic Syndr. 2000;  25 99-102
• 31 Finke P E, Meurer L C, Oates B. et al . Antagonists of the human CCR5 receptor as anti-HIV-1 agent.  Bioorg Med Chem Lett. 2001;  11 265-270

Korrespondenz